EDF Health

Selected tag(s): Tox21

“Big data” comes to chemical testing – How to ensure more is better

Jonathan Choi is a chemicals policy fellow.

EDF Senior Scientist Dr. Jennifer McPartland contributed to this post.

The beginning of this century will no doubt be known for a lot of things. In the biological sciences, I predict it’ll be known for big data. It’s hard to wrap your head around just how far we’ve come already. For example, the data chips that sing “happy birthday” to your loved ones in those horrendously overpriced cards have more computing power than the Allies did in 1945. When I first started using computers, the 5.4” floppy disk was being replaced by the new 256Kb 3.5” disk. Now in Korea, you can get 1 GB per second internet speeds for $20 a month. That’s around 4000 floppy disks of data per second for about as much as I spend every week at the burrito place down the street.

In the biological sciences, we’ve seen an explosion of new ways to generate, collect, analyze, and store data. We’re photographing the world’s biodiversity and sharing it with crowdsourced taxonomists. We’re creating a database of the genomes of the world’s organisms. We’re mapping chemical exposures (our exposome), inventorying the microbes that live in our guts (our microbiome), ripping apart cells and sequencing every bit of messenger RNA that floats around inside (our transcriptome), and much more.

So, it’s not too surprising that regulatory agencies like EPA are pushing their own efforts to amass large quantities of data to help meet their missions. EPA has the unenviable task of reviewing tens of thousands of chemicals currently on the market with little health and safety data, on top of hundreds of new chemicals banging at its door each year. As we have written on numerous occasions, the agency clearly needs a better law that gives it greater authority to get the data it needs to effectively evaluate and manage chemical risks. But, given the information abyss in which we operate, we could definitely stand to adopt new testing approaches that generate at least screening level data on chemicals faster.   Read More »

Posted in Emerging science, Emerging testing methods, Health science / Also tagged , | Comments are closed

21st Century on the horizon for endocrine disruptor screening?

Rachel Shaffer is a research assistant. Jennifer McPartland, Ph.D., is a Health Scientist.

BPA, DDT, PCBs, PBDEs, phthalates, PFOA … Forgive the alphabet soup, but chances are you’ve heard of at least some of these endocrine-disrupting chemicals (EDCs), which have been the subject of a lot of public and media attention in the last several years. Research has begun to uncover the ways in which these chemicals can interact with the body’s hormone – or endocrine – system to disrupt various natural biological processes, including metabolism, the reproductive system, and development of the brain and nervous systems.

While the endocrine-disrupting properties of the chemicals named above have been confirmed, scientists suspect there may be many more such chemicals in our environment, in the products we use, and in our bodies.  How can we identify them?

Legislation enacted in 1996 required the U.S. Environmental Protection Agency (EPA) to develop a screening program to identify potential EDCs.  More than 10 years later, EPA finally launched the Endocrine Disruptor Screening Program (EDSP).  Testing is being conducted in two phases, or “tiers.”  In “Tier 1,” a screening battery of validated in vivo and in vitro assays is used to identify chemicals with potential to interfere with the endocrine system. Chemicals flagged in the first tier of testing are then subject to “Tier 2” testing intended to determine the specific effect and the lowest dose at which it occurs. (We should note this program is very controversial and the subject of ongoing debate, but that is not the subject of this post.)

EPA has identified an estimated 9,700 chemicals to be screened – a very daunting task given the time- and resource-intensive nature of the testing battery EPA has established.  Might there be a way to expedite the identification and testing of the more problematic chemicals? A study published earlier this year in Environmental Health Perspectives (EHP) investigates a possible approach: using in vitro high-throughput (HT) assays developed through EPA’s ToxCast and Tox21 programs to target and prioritize chemicals for further testing under the EDSP. While use of these assays poses its own challenges, might it at least help in determining an appropriate testing sequence?  Read More »

Posted in Emerging testing methods, Health science / Also tagged , , , , , , , | Comments are closed

Variety is the spice of … accurate chemical testing

Rachel Shaffer is a research assistant.  Jennifer McPartland, Ph.D., is a Health Scientist.

There has been a lot of buzz in recent years about the federal government’s new chemical testing initiatives, ToxCast and Tox21 (see, for example, these articles in Scientific American and the New York Times).  These programs are developing high-throughput (HT) in-vitro testing to evaluate—and ultimately predict—the biological effects of chemicals.  In contrast to the relatively slow pace of traditional animal testing, ToxCast and Tox21 use sophisticated robots to rapidly test thousands of chemicals at a time. As a result, they hold the potential to more efficiently fill enormous gaps in available health data, predict adverse effects, and shed light on exactly how chemicals interact and interfere with our biology. (For more on these potential benefits, see Section 5 of EDF’s Chemical Testing Primer).

Yet, among the key challenges that these new methods must address is one that traditional, animal-based methods have faced for decades: how can laboratory testing adequately account for the high degree of variability in the human population? The latest research suggests the exciting possibility that genetic diversity, at least, may be able to be incorporated into emerging HT in vitro approaches.   Read More »

Posted in Emerging testing methods, Health science / Also tagged , , , , , | Read 2 Responses

EDF launches website on EPA’s emerging chemical testing programs

Jennifer McPartland, Ph.D., is a Health Scientist.

New approaches for evaluating chemical hazard and risk are needed to help address substantial data gaps that exist for the thousands of chemicals currently in the marketplace as well as those yet to be introduced.   EPA has been investing significant resources to create research programs dedicated to advancing new types of chemical testing and assessment approaches.  But what exactly are these approaches?  How might they improve the practice of risk assessment?  Are they appropriate for decision-making, and if so, what kinds of decision making?  What role does the public interest community have to play? 

To explore these and other important issues, EDF’s Health Program has launched a website, “Chemical Testing in the 21st Century,” that provides an  introduction to these new approaches and the programs the EPA has built around them—including their potential uses, benefits and limitations.  The website includes the following informational resources: 

  1. Chemical Testing in the 21st Century: A Primer – An introduction to EPA’s Computational Toxicology (CompTox) research initiative and its component programs, such as ToxCast; a discussion of the opportunities and challenges of these new testing programs; and a discussion of issues and needs for greater engagement by the public interest community.  
  2. Chemical Testing in the 21st Century: Webinar Series – Linked audio and video recordings of each of EDF’s three webinars (held in October) featuring EDF and EPA scientists exploring the basics of EPA’s new testing programs and the promises and challenges they present. 

We will soon be adding a page with descriptions of and links to additional resources.

Posted in Emerging testing methods, Health science / Also tagged , , , , , , , | Comments are closed

Chemical safety evaluation: Packing tox tests into single drops of liquid!

Jennifer McPartland, Ph.D., is a Health Scientist.

Parts in this series:      Part 1     Part 2     Part 3     Part 4

In my last post I introduced EPA’s collaborative NexGen effort and briefly described the scientific advances underpinning the program.  In this post, I’ll explore some of the potential power of EPA’s efforts, which will require that we get a bit into the nitty gritty (nerd spoiler alert!).

NexGen is focusing on how new scientific knowledge and technological capabilities may interplay with traditional hazard and risk assessment that predominantly relies on more expensive and time-consuming animal studies.

There has been a lot of buzz around what is called high-throughput (HT) testing of chemicals.  Just last week, EPA issued a public statement describing the unveiling of a new robot housed at the National Institutes of Health Chemical Genomics Center (NCGC).  I highly recommend watching the robot in action by clicking on the “Toxicity Testing Robot System” video link available on the NIH National Human Genome Research Institute’s website.  The robot is scheduled to test 10,000 chemicals for potential toxicity!   So, what does that actually mean?  Read More »

Posted in Emerging testing methods, Health science / Also tagged , , , | Comments are closed